Apica Cardiovascular Ltd.
Standardized apical access and closure for treating structural heart diseases
This article was originally published in Start Up
Executive Summary
Apica Cardiovascular is leading the field of transapical access and closure for structural heart disease. Its first product is a titanium coil that stabilizes the surgical access site in the apex of the heart to prevent bleeding during and after therapeutic interventions and provides for reaccess in the future. Also in the works are a large closure device for transfemoral access closure and a connector that aids in the delivery and implantation of newer, smaller, left ventricular assist devices through the Apica coil.
You may also be interested in...
Thoratec Seeks Less Invasive VAD Access With Apica Acquisition
The completed deal calls for $35 million up front and $40 million in future clinical and sales milestones. Apica is developing systems to assist transapical surgical access for ventricular assist devices and transcatheter valve replacements.
Medical Device Start-Up News, August 2012
This month we profile CoolSpine and its catheter-based hypothermia device, Inseal Medical and its large-bore vascular closure device, and MitrAssist Medical, which is developing a valve-in-valve approach to treating mitral regurgitation.
Medtech in Ireland -- Turning Green into Gold
Despite the recent downturn in the national economy, Ireland's medical device community is on the verge of a major growth spurt. A lot of the credit goes to strong government support, particularly in the form of Enterprise Ireland, which serves as a major investor in medtech start-ups. Even with such support, Ireland's medtech start-up community faces many of the challenges that any start-up community faces. But the sector has high hopes and great ambitions. The second of a two-part series.